CJC-1295, the Drug Affinity Complex, and the Half-Life That Defines It

The difference between CJC-1295 with and without DAC is not a formulation detail — they are chemically different molecules whose half-lives differ by roughly three orders of magnitude. CJC-1295 with DAC carries a Drug Affinity Complex: a maleimide group that forms a covalent bond with circulating albumin, giving a measured half-life in healthy adults of several days 2. "CJC-1295 without DAC" carries no such group. It is modified GRF(1-29), a 29-residue peptide cleared in minutes. The two are marketed under names separated by three letters and behave nothing alike. Every study in the published CJC-1295 literature — the rat receptor work, the knockout mouse work, the human pharmacokinetics — was conducted with the albumin-binding molecule 1234.

The clearance problem native GHRH has

Growth hormone-releasing hormone is a 44-residue peptide released from the hypothalamus and delivered to the anterior pituitary through the hypophyseal portal circulation. It is designed to be transient. Its plasma half-life is measured in minutes, and the reason is a single, well-characterised enzyme.

Dipeptidyl peptidase-4 is a serine exopeptidase found in plasma and anchored to endothelial surfaces. It removes N-terminal dipeptides from substrates carrying proline or alanine at position 2. GHRH has alanine at position 2. Cleavage produces GHRH(3-44), which no longer activates the receptor. The same enzyme is what terminates GLP-1 signalling, which is why the two peptide families have converged on similar chemical solutions.

Receptor recognition sits at the N-terminus. The C-terminal fifteen residues can be removed without meaningful loss of potency, and GHRH(1-29) is the shortest fragment that retains essentially full activity. Synthesised as a pharmaceutical, that fragment is sermorelin. Shortening the chain, however, does nothing about the clearance route: alanine still occupies position 2, DPP-4 still cleaves it, and the half-life is still measured in minutes. Truncation defines the active core. It does not solve the pharmacokinetics.

Four substitutions: modified GRF(1-29)

Modified GRF(1-29) is GRF(1-29) with four amino acid substitutions, each addressing a specific molecular liability rather than being an arbitrary tweak. The design logic is worth setting out individually, because it explains what the molecule is and is not protected against.

• Position 2: alanine replaced by D-alanine. The enzyme's active site cannot accommodate the D-isomer, so the principal proteolytic route is blocked at source.
• Position 8: asparagine replaced by glutamine. Asparagine at this position undergoes deamidation and a backbone rearrangement to an inactive isoaspartate form. This is a chemical instability, not an enzymatic one, and it limits the peptide's shelf life as well as its behaviour in plasma.
• Position 15: glycine replaced by alanine. Glycine confers unusual backbone flexibility; substituting alanine constrains the region and is associated with increased potency at the receptor.
• Position 27: methionine replaced by leucine. Methionine oxidises readily to the sulfoxide. Leucine is close in size and shape and cannot oxidise.

The result is a peptide substantially harder to degrade. It is not a long-acting peptide, because degradation was never the only clearance route. At roughly 3.4 kDa, modified GRF(1-29) is far below the glomerular filtration threshold of approximately 60 to 70 kDa. The kidney filters it regardless of how protease-resistant it has been made. Its half-life stays in the range of minutes.

The Drug Affinity Complex

CJC-1295 addresses the size problem rather than the enzyme problem. The peptide is extended by a lysine at position 30, and that lysine's side-chain amine carries a maleimidopropionyl group. Maleimide is a thiol-selective electrophile: at physiological pH it undergoes Michael addition with free sulfhydryl groups, forming a thioether bond that does not reverse. The name Drug Affinity Complex understates the chemistry. The attachment is covalent.

The target is specific by default rather than by design. Human serum albumin contains 35 cysteine residues, 34 of which are locked into 17 disulfide bridges. Cysteine-34 is the sole free thiol in the protein and, given albumin's abundance, the most plentiful free thiol in plasma. A maleimide-bearing peptide entering the circulation will find it. Conjugation happens in vivo, after administration, rather than being manufactured in advance.

What the peptide gains is albumin's pharmacokinetics. Albumin is roughly 66.5 kDa, comfortably above the filtration threshold, and it is rescued from lysosomal degradation by the neonatal Fc receptor and recycled — a mechanism that gives it a plasma half-life of around nineteen days in humans. A peptide covalently tethered to that carrier is no longer a small molecule from the kidney's perspective. It is also sterically shielded from many proteases. The tether converts a clearance profile measured in minutes into one measured in days.

The non-obvious question is whether a peptide anchored to a 66 kDa protein can still engage a receptor at all. Steric occlusion is a real failure mode for conjugates of this kind. The 2005 Endocrinology work answered it directly: hGRF(1-29)-albumin bioconjugates activated the GRF receptor on the anterior pituitary in rats, and that study is where CJC-1295 was identified as a long-lasting GRF analogue 1. Retained receptor activity was a finding, not an assumption.

Why the naming matters more than usual

CJC-1295 is a specific development code for a specific compound: the tetrasubstituted GRF(1-29) analogue bearing the albumin-binding linker. "CJC-1295 without DAC" is therefore close to a contradiction in terms. The DAC is not an optional feature bolted onto CJC-1295; it is the modification that made the compound worth naming. Strip it out and what remains is modified GRF(1-29), a peptide that already had its own name before the conjugate existed.

This is not pedantry about nomenclature. It has a direct consequence for anyone reading around the compound. Search results, summaries and product descriptions routinely attach the human pharmacokinetic findings — the multi-day half-life, the sustained IGF-I elevation — to material that has none of the chemistry those findings depend on. The half-life figure belongs to the albumin conjugate and to nothing else. Applied to the unconjugated peptide it is wrong by a factor of roughly a thousand.

Mechanism at the somatotroph

The GHRH receptor is a class B G protein-coupled receptor of the secretin family, expressed on somatotroph cells of the anterior pituitary. Binding couples to Gs, which activates adenylyl cyclase and raises intracellular cAMP. Protein kinase A activation follows, with two consequences on different timescales. Acutely, membrane depolarisation and calcium influx trigger exocytosis of pre-formed GH granules. Over longer periods, CREB phosphorylation drives transcription of the pituitary-specific transcription factor Pit-1 and of the GH gene itself, increasing synthetic capacity as well as release. Sustained GHRH signalling is also trophic for the somatotroph population.

The control architecture is the part that distinguishes a secretagogue from growth hormone itself. GHRH acts one level upstream, on a cell that is subject to its own regulation. Somatostatin, released from the hypothalamic periventricular nucleus, acts on Gi-coupled somatostatin receptors on the same somatotrophs and lowers cAMP — directly antagonising the GHRH signal at the second messenger. IGF-I, produced largely by the liver in response to GH, feeds back at both the pituitary and the hypothalamus. GH output is therefore not a linear function of GHRH stimulation. It is the output of a loop with active brakes.

Administering growth hormone bypasses that loop entirely: the hormone arrives downstream of every regulatory element that would otherwise constrain it. This is a genuine mechanistic difference and it is the argument routinely made for secretagogues as a class. It is worth being precise about what it does and does not imply. It implies a ceiling on attainable GH concentrations imposed by feedback. It does not by itself demonstrate a better safety profile, which is a claim about outcomes and requires outcome data.

Pulsatility persists under continuous stimulation

Growth hormone is not secreted at a steady rate. It is released in discrete bursts separated by near-undetectable troughs, with the largest pulses during slow-wave sleep. A compound with a half-life of days delivers something close to continuous receptor occupancy, and the obvious prediction is that continuous stimulation flattens the pulse profile into a plateau. That prediction was tested in humans and did not hold: pulsatile GH secretion persisted during continuous stimulation by CJC-1295, with pulse frequency preserved and pulse amplitude increased 4.

The mechanistic explanation is consistent with the feedback architecture described above. Pulse troughs are generated largely by oscillating somatostatin tone, which is driven independently of GHRH input. A constant GHRH signal raises the amplitude of what the somatotroph releases when the brake is off, but it does not remove the brake or alter its rhythm. The pattern generator sits upstream of the drug.

This matters because GH signalling is pattern-dependent, not merely concentration-dependent. Downstream transduction through STAT5b, and the hepatic gene expression programmes it controls, respond differently to pulsatile versus continuous exposure — a distinction established most clearly in rodents, where it underlies sexually dimorphic liver gene expression. A long-acting stimulus that preserves the secretory pattern is, in principle, a different pharmacological object from one that clamps GH at a plateau. The qualification: preserved pulsatility is a pharmacodynamic observation, not a demonstration that any clinical endpoint improves.

What the human data actually shows

Human pharmacokinetic and pharmacodynamic data exists for this compound, and that is genuinely unusual for a peptide discussed in this category. Most compounds in the same conversation have rodent data, in vitro data, and nothing else. CJC-1295 was studied in healthy adults, with measured concentrations and measured hormonal responses 2.

The reported half-life was 5.8 to 8.1 days. Growth hormone concentrations rose approximately two- to ten-fold and remained elevated for around six days after a single administration. IGF-I rose approximately 1.5- to three-fold and stayed elevated for nine to eleven days 2. The sustained IGF-I response is the clearer signal, because IGF-I integrates GH exposure over time and is not subject to the sampling problems that pulsatile GH measurement creates.

What that study establishes is that the albumin-conjugation strategy works as designed in humans: the compound persists, it reaches the pituitary, and the pituitary responds for as long as the compound is present. What it does not establish is any clinical outcome. GH and IGF-I concentrations are biomarkers. They are the mechanism reporting on itself, not evidence that anything downstream of the mechanism improved. Body composition, function, recovery and long-term safety were not the endpoints.

The animal work complements this rather than extending it. In the GHRH knockout mouse — an animal with no endogenous GHRH signal at all — administration on a daily schedule normalised growth 3. That is a clean demonstration of on-target activity: the compound substitutes for a signal the animal genuinely lacks. It is also, for that reason, a deficiency model, and correcting an absent signal does not describe what the compound does where the signal is already intact.

What the evidence does not establish

• No clinical outcome has been demonstrated. The human evidence addresses hormone concentrations and pharmacokinetics, not body composition, physical function, injury recovery or any disease endpoint.
• Long-term safety is unstudied. Sustained IGF-I elevation is simultaneously the intended pharmacological effect and the principal theoretical safety concern, and no long-duration human dataset addresses it.
• The covalent bond is not reversible on any useful timescale. Once conjugation has occurred, exposure continues for as long as that albumin molecule circulates — there is no mechanism for rapid withdrawal.
• Effects in GH-sufficient humans cannot be inferred from the knockout mouse, where the entire finding depends on the animal having no GHRH to begin with.
• Nothing in this literature characterises modified GRF(1-29) as a distinct product. Material sold as "CJC-1295 without DAC" has no published human pharmacokinetic profile under either name.
• Purity and identity of research-supplied material are not independently established. A conjugation strategy that depends on an intact, correctly positioned maleimide is particularly sensitive to synthesis and storage quality.

How to read this literature

Three checks resolve most of the confusion here. First, establish whether the source describes the albumin conjugate or the unconjugated peptide, because every pharmacokinetic figure in the literature belongs to the former and none transfers to the latter. Second, separate biomarker outcomes from clinical outcomes: elevated GH and IGF-I confirm a GHRH receptor agonist is doing what such an agonist does, which is a mechanism check rather than a benefit. Third, note the model system, and treat the GHRH knockout mouse as evidence about on-target activity in a deficiency state.

The engineering behind CJC-1295 is a well-documented solution to a specific problem: a short peptide with a valuable activity and an impractically short residence time. Four substitutions removed the degradation routes; one covalent tether to albumin removed the filtration route. The published human data confirms the strategy worked at the level of pharmacokinetics and hormone response. The persistent error is not about the chemistry. It is the assumption that a shared name implies a shared pharmacology, when the point of the name is a feature only one of the two molecules has.